This trial is conducted in Europe.

The aim of this trial is to investigate the safety and efficacy of insulin detemir combined with oral anti-diabetic drugs (OADs) versus insulin NPH combined with oral anti-diabetic drugs (OADs) in Type 2 mellitus not well controlled on current therapy on blood glucose control.

Inclusion Criteria:

• Type 2 diabetes for at least 12 months since diagnosis
• Insulin naive subjects
• OAD treatment for at least 4 months alone or combined with no more than two OADs
• Body mass index (BMI) below 35.0 kg/m2
• HbA1c between 7.5-10.0%
• Able and willing to use twice a day injections for the entire trial period

Exclusion Criteria:

• Current or previous treatment with thiazolidiones within the last 6 months
• OAD treatment with three or more OADs within the last 6 months
• Acute insulin treatment for longer than 7 days in a row within the last 6 months
• Secondary diabetes
• Known maturity onset of diabetes of young (MODY)
• Known or suspected allergy to trial product or related products